Prognostic impact of bone metastatic volume beyond vertebrae and pelvis in patients with metastatic hormone-sensitive prostate cancer.
Bone metastasis
Bone scan index
Metastatic hormone sensitive prostate cancer
Risk classification
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
17
02
2021
accepted:
01
05
2021
pubmed:
29
5
2021
medline:
29
5
2021
entrez:
28
5
2021
Statut:
ppublish
Résumé
Although bone metastasis beyond the vertebrae and pelvis has been a key factor in prognostic models of metastatic hormone-sensitive prostate cancer (mHSPC), the clinical significance of it is still unclear. The present study evaluated the prognostic impact of the volume of bone metastasis beyond the vertebrae and pelvis on the outcomes of mHSPC and created an ideal risk classification based on it. We retrospectively reviewed 197 patients with mHSPC who were treated with combined androgen blockade as the initial treatment between June 2003 and October 2019. We calculated the bone scan index (BSI), including the BSI beyond the vertebrae and pelvis (bBSI), using BONENAVI, and investigated the association between the BSI and the overall survival (OS) of mHSPC. According to the CHAARTED criteria, 91 and 106 patients were classified into the low- and high-volume groups, respectively. Of the 79 patients who did not have visceral metastasis in the high-volume group, those with a bBSI ≤ 0.27 (n = 16) showed a favorable OS, as did those in the low-volume group. The modified CHAARTED high-volume group (presence of visceral metastases or 4 bone lesions with a bBSI > 0.27) showed a significantly shorter OS than others, with a hazard ratio (HR) of 4.69 (p < 0.001), which was higher than that observed with the original CHAARTED criteria (HR = 4.33). Our data suggested that considering the volume of bone metastasis beyond the vertebrae and pelvis may help to improve the accuracy of risk classification. Further large-scale prospective studies are needed to validate our findings.
Sections du résumé
BACKGROUND
BACKGROUND
Although bone metastasis beyond the vertebrae and pelvis has been a key factor in prognostic models of metastatic hormone-sensitive prostate cancer (mHSPC), the clinical significance of it is still unclear. The present study evaluated the prognostic impact of the volume of bone metastasis beyond the vertebrae and pelvis on the outcomes of mHSPC and created an ideal risk classification based on it.
METHODS
METHODS
We retrospectively reviewed 197 patients with mHSPC who were treated with combined androgen blockade as the initial treatment between June 2003 and October 2019. We calculated the bone scan index (BSI), including the BSI beyond the vertebrae and pelvis (bBSI), using BONENAVI, and investigated the association between the BSI and the overall survival (OS) of mHSPC.
RESULTS
RESULTS
According to the CHAARTED criteria, 91 and 106 patients were classified into the low- and high-volume groups, respectively. Of the 79 patients who did not have visceral metastasis in the high-volume group, those with a bBSI ≤ 0.27 (n = 16) showed a favorable OS, as did those in the low-volume group. The modified CHAARTED high-volume group (presence of visceral metastases or 4 bone lesions with a bBSI > 0.27) showed a significantly shorter OS than others, with a hazard ratio (HR) of 4.69 (p < 0.001), which was higher than that observed with the original CHAARTED criteria (HR = 4.33).
CONCLUSIONS
CONCLUSIONS
Our data suggested that considering the volume of bone metastasis beyond the vertebrae and pelvis may help to improve the accuracy of risk classification. Further large-scale prospective studies are needed to validate our findings.
Identifiants
pubmed: 34047889
doi: 10.1007/s10147-021-01931-x
pii: 10.1007/s10147-021-01931-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1533-1540Informations de copyright
© 2021. Japan Society of Clinical Oncology.
Références
Global Burden of Disease Cancer C, Fitzmaurice C, Akinyemiju TF et al (2018) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 4(11):1553–1568
doi: 10.1001/jamaoncol.2018.2706
Yap TA, Zivi A, Omlin A et al (2011) The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 8(10):597–610
doi: 10.1038/nrclinonc.2011.117
Kelly SP, Anderson WF, Rosenberg PS et al (2018) Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus 4(1):121–127
doi: 10.1016/j.euf.2017.10.014
Dall’Era MA, deVere-White R, Rodriguez D et al (2019) Changing incidence of metastatic prostate cancer by race and age, 1988–2015. Eur Urol Focus 5(6):1014–1021
doi: 10.1016/j.euf.2018.04.016
Huggins C, Hodges CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941. J Urol 168(1):9–12
doi: 10.1016/S0022-5347(05)64820-3
Laufer M, Denmeade SR, Sinibaldi VJ et al (2000) Complete androgen blockade for prostate cancer: what went wrong? J Urol 164(1):3–9
doi: 10.1016/S0022-5347(05)67436-8
Cattrini C, Castro E, Lozano R et al (2019) Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers (Basel) 11(9):1355
doi: 10.3390/cancers11091355
Cornford P, van den Bergh RCN, Briers E et al (2020) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. https://doi.org/10.1016/j.eururo.2020.09.046
doi: 10.1016/j.eururo.2020.09.046
pubmed: 33172724
pmcid: 7183974
Crawford ED, Eisenberger MA, McLeod DG et al (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321(7):419–424
doi: 10.1056/NEJM198908173210702
Eisenberger MA, Blumenstein BA, Crawford ED et al (1998) Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer. N Engl J Med 339(15):1036–1042
doi: 10.1056/NEJM199810083391504
Hussain M, Tangen CM, Berry DL et al (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368(14):1314–1325
doi: 10.1056/NEJMoa1212299
Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373(8):737–746
doi: 10.1056/NEJMoa1503747
Poulsen MH, Rasmussen J, Edenbrandt L et al (2016) Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer. BJU Int 117(5):748–753
doi: 10.1111/bju.13160
Miyoshi Y, Yoneyama S, Kawahara T et al (2016) Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. BMC Cancer 16:128
doi: 10.1186/s12885-016-2176-6
Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61(1):195–202
doi: 10.1002/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y
Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148–1159
doi: 10.1200/JCO.2007.12.4487
Koizumi M, Wagatsuma K, Miyaji N et al (2015) Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting. Ann Nucl Med 29(2):138–148
doi: 10.1007/s12149-014-0921-y
Yamada Y, Sakamoto S, Rii J et al (2020) How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: A retrospective multicenter cohort study. Prostate 80(5):432–440
doi: 10.1002/pros.23958
Akamatsu S, Kubota M, Uozumi R et al (2019) Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naive Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol 2(3):320–328
doi: 10.1016/j.euo.2018.10.011
Narita S, Hatakeyama S, Takahashi M et al (2020) Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan. Int J Clin Oncol 25(5):912–920
doi: 10.1007/s10147-019-01614-8
Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361–387
doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48(3):452–458
doi: 10.1038/bmt.2012.244
Shiota M, Namitome R, Kobayashi T et al (2019) Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer. Int J Urol 26(3):426–428
doi: 10.1111/iju.13870
Hatakeyama S, Narita S, Takahashi M et al (2020) Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study. Int J Urol 27(7):610–617
doi: 10.1111/iju.14258
Ulmert D, Kaboteh R, Fox JJ et al (2012) A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 62(1):78–84
doi: 10.1016/j.eururo.2012.01.037
Report of the task group on reference man (1979). Ann ICRP 3 (1–4):iii
Fukagai T, Namiki TS, Carlile RG et al (2006) Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 97(6):1190–1193
doi: 10.1111/j.1464-410X.2006.06201.x
Bernard B, Muralidhar V, Chen YH et al (2017) Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer 123(9):1536–1544
doi: 10.1002/cncr.30503
Fukasawa S, Suzuki H, Kawaguchi K et al (2018) Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. Jpn J Clin Oncol 48(11):1012–1021
doi: 10.1093/jjco/hyy129